Drug Trial Radar · NCT01650805
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
307
Actual
Start
Jun 2012
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- Ariad PharmaceuticalsTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Jul 26, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy of ponatinib and imatinib in patients with newly diagnosed chronic myeloid leukemia (CML) in the chronic phase.
Conditions
- Chronic Myeloid Leukemia
Interventions
ponatinibDrug
45 mg tablet, taken orally once daily
imatinib (Gleevec/ Glivec)Drug
400 mg tablet, taken orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Molecular Response (MMR) Rate at 12 MonthsTime frame: 12 months after first dose
Locations
170 sites in 24 countries. Site status is shown where the registry gives one.
US Oncology - Providence Health System, Site #167
Burbank, California
UCLA Department of Medicine, Site #027
Los Angeles, California
Bay Area Cancer Research Group, Site #156
Pleasant Hill, California
Bay Area Cancer Research Group, Site #157
Pleasant Hill, California
Rocky Mountain Cancer Centers, Site #191
Boulder, Colorado
Cancer Center of Central Connecticut, Site #147
Southington, Connecticut
Christiana Care Health Services, Site #155
Newark, Delaware
University Cancer Institute, Site #149
Boynton Beach, Florida
Florida Cancer Specialists, Site #180
Fort Meyers, Florida
Florida Cancer Specialists, Site #179
St. Petersburg, Florida
Emory University, Site #058
Atlanta, Georgia
John H. Stroger, Jr. Hospital of Cook County, Site #192
Chicago, Illinois
University of Chicago, Site #001
Chicago, Illinois
Loyola University Chicago, Site #054
Maywood, Illinois
Franciscan St. Francis Health, Site #138
Indianapolis, Indiana
University of Iowa Hospitals and Clinics, Site #050
Iowa City, Iowa
Siouxland Hematology-Oncology Associates, Site #198
Sioux City, Iowa
US Oncology - Cancer Center of Kansas, Site #168
Wichita, Kansas
Willis-Knighton Cancer Center, Site #196
Shreveport, Louisiana
University of Maryland, Greenebaum Cancer Center, Site #040
Baltimore, Maryland
Greater Baltimore Medical Center, Site #140
Baltimore, Maryland
St. Agnes Healthcare, Site #185
Baltimore, Maryland
Massachusetts General Hospital, Site #047
Boston, Massachusetts
Dana Farber Cancer Institute, Site #008
Boston, Massachusetts
University of Massachusetts Worcester, Site #152
Worcester, Massachusetts
University of Michigan Medical Center, Site #011
Ann Arbor, Michigan
Providence Cancer Institute, Site #197
Southfield, Michigan
Mayo Clinic, Site #044
Rochester, Minnesota
Oncology Research Park Nicollet Institute, Site #195
Saint Louis Park, Minnesota
Saint Luke's Hospital, Site #162
Kansas City, Missouri
Mercy Clinic - Cancer & Hematology, Site #151
Springfield, Missouri
Nebraska Hematology-Oncology, P.C., Site # 133
Lincoln, Nebraska
US Oncology - Comprehensive Cancer Center of Nevada, Site #169
Las Vegas, Nevada
John Theurer Cancer Center, Site #128
Hackensack, New Jersey
University of New Mexico Cancer Center, Site #166
Albuquerque, New Mexico
Maimonides Cancer Center, Site #177
Brooklyn, New York
Winthrop University Hospital, Site #153
Mineola, New York
Beth Israel Medical Center, Site #145
New York, New York
Mount Sinai School of Medicine, Site #189
New York, New York
Memorial Sloan-Kettering Cancer Center, Site #078
New York, New York
Showing 40 of 170 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.